{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:18:33Z","timestamp":1778509113284,"version":"3.51.4"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03CA224339"],"award-info":[{"award-number":["R03CA224339"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2P30CA036727"],"award-info":[{"award-number":["2P30CA036727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010537","name":"Nebraska Department of Health and Human Services","doi-asserted-by":"publisher","award":["LB506"],"award-info":[{"award-number":["LB506"]}],"id":[{"id":"10.13039\/100010537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002300","name":"Rivkin Center for Ovarian Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM127200"],"award-info":[{"award-number":["P30GM127200"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001282","name":"Ovarian Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jconrel.2023.07.033","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T06:34:58Z","timestamp":1690439698000},"page":"872-887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer"],"prefix":"10.1016","volume":"360","author":[{"given":"Xinyuan","family":"Xi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rihe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam R.","family":"Karpf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana K.","family":"Bronich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.07.033_bb0005","first-page":"1","article-title":"Combination drug delivery approaches in metastatic breast cancer","volume":"2012","author":"Lee","year":"2012","journal-title":"J. Drug. Deliv."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0010","series-title":"Holland-Frei Cancer Medicine, Holland-Frei Cancer Medicine","author":"Bast","year":"2000"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/156800906778194586","article-title":"Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers","volume":"6","author":"Waterhouse","year":"2006","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0020","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.2174\/1381612821666150531165059","article-title":"Nanoparticle-based combination therapy for cancer treatment","volume":"21","author":"Yhee","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","article-title":"Nanomedicine of synergistic drug combinations for cancer therapy - strategies and perspectives","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jconrel.2013.04.026","article-title":"Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer","volume":"171","author":"Desale","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0035","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2017.08.038","article-title":"Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer","volume":"264","author":"Soni","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1124\/jpet.118.255786","article-title":"Combination therapies and drug delivery platforms in combating pancreatic cancer","volume":"370","author":"Lei","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0045","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1124\/jpet.118.255372","article-title":"A polymeric nanogel-based treatment regimen for enhanced efficacy and sequential administration of synergistic drug combination in pancreatic cancer","volume":"370","author":"Soni","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0050","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3109\/10717544.2013.863526","article-title":"Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation","volume":"22","author":"Tang","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0055","series-title":"Key Statistics for Ovarian Cancer","year":"2023"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0060","first-page":"447","article-title":"EGFR\/HER-targeted therapeutics in ovarian cancer, future","volume":"4","author":"Wilken","year":"2012","journal-title":"Med. Chem."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0065","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ogc.2018.09.005","article-title":"Ovarian Cancer: clinical trial breakthroughs and impact on management","volume":"46","author":"Previs","year":"2019","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0075","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3390\/ijms20174136","article-title":"New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment","volume":"20","author":"Chen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0080","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0085","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1078-0432.CCR-04-1544","article-title":"The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy","volume":"11","author":"Warshamana-Greene","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0090","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0095","first-page":"571","article-title":"Sensitization of HER-2\/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin","volume":"12","author":"Zhang","year":"1996","journal-title":"Oncogene."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/568938","article-title":"Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges","volume":"2010","author":"Siwak","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00109-006-0054-4","article-title":"Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma","volume":"84","author":"Lassus","year":"2006","journal-title":"J. Mol. Med. (Berl)."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0002-9378(11)80044-X","article-title":"Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer","volume":"164","author":"Berchuck","year":"1991","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0960-0760(90)90425-K","article-title":"Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer","volume":"37","author":"Foekens","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0125","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1038\/sj.onc.1209737","article-title":"Cisplatin induces PKB\/Akt activation and p38(MAPK) phosphorylation of the EGF receptor","volume":"25","author":"Winograd-Katz","year":"2006","journal-title":"Oncogene."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s11596-011-0675-x","article-title":"EGFR inhibitor enhances cisplatin sensitivity of human glioma cells","volume":"31","author":"Zhang","year":"2011","journal-title":"J. Huazhong. Univ. Sci. Technol. Med. Sci."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0135","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1007\/s13277-014-1902-4","article-title":"Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin","volume":"35","author":"Song","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0140","doi-asserted-by":"crossref","first-page":"27117","DOI":"10.1074\/jbc.M602826200","article-title":"The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment","volume":"281","author":"Colton","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/cr.2015.8","article-title":"Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response","volume":"25","author":"Lee","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0150","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.devcel.2014.06.008","article-title":"EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4","volume":"30","author":"Chou","year":"2014","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0155","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/OTT.S77283","article-title":"Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair","volume":"8","author":"Teng","year":"2015","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0160","doi-asserted-by":"crossref","first-page":"8723","DOI":"10.1038\/sj.onc.1205980","article-title":"Cisplatin-induced activation of the EGF receptor","volume":"21","author":"Benhar","year":"2002","journal-title":"Oncogene."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2014.08.006","article-title":"Neratinib shows efficacy in the treatment of HER2\/neu amplified uterine serous carcinoma in vitro and in vivo","volume":"135","author":"Schwab","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0170","first-page":"107","article-title":"EGFR and HER2: is there a role in ovarian cancer?, Translat","volume":"4","author":"Teplinsky","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0175","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1158\/1078-0432.CCR-18-1131","article-title":"Extended adjuvant therapy with neratinib plus fulvestrant blocks ER\/HER2 crosstalk and maintains complete responses of ER+\/HER2+ breast cancers: implications to the ExteNET trial","volume":"25","author":"Sudhan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0180","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ijc.2910570614","article-title":"Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle","volume":"57","author":"Donaldson","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1097-0215(19960717)67:2<224::AID-IJC13>3.0.CO;2-B","article-title":"Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not C-RAF-1 protein","volume":"67","author":"Warenius","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0190","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-04-2419","article-title":"Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line","volume":"11","author":"Biliran","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0195","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1021\/mp5000373","article-title":"Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity","volume":"11","author":"Liu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0200","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.20045","article-title":"Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid","volume":"92","author":"Marchion","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0205","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602772","article-title":"Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats","volume":"93","author":"Uchino","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0210","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acsami.9b02756","article-title":"ROS-responsive polymeric micelles for triggered simultaneous delivery of PLK1 inhibitor\/miR-34a and effective synergistic therapy in pancreatic cancer","volume":"11","author":"Xin","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biomaterials.2018.10.036","article-title":"Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer","volume":"192","author":"Lin","year":"2019","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0220","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2015.11.009","article-title":"Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation","volume":"240","author":"Soni","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0230","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1021\/bm900252d","article-title":"Enhanced cytoplasmic delivery of siRNA using a stabilized polyion complex based on PEGylated nanogels with a cross-linked polyamine structure","volume":"10","author":"Tamura","year":"2009","journal-title":"Biomacromolecules."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0235","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1016\/j.biomaterials.2013.03.050","article-title":"Photo-crosslinked hyaluronic acid nanoparticles with improved stability for in vivo tumor-targeted drug delivery","volume":"34","author":"Yoon","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0240","doi-asserted-by":"crossref","first-page":"24462","DOI":"10.1021\/acsami.7b05617","article-title":"EGFR\/EGFRvIII dual-targeting peptide-mediated drug delivery for enhanced glioma therapy","volume":"9","author":"Mao","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0245","author":"Liu"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0250","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/2326-6066.CIR-18-0636","article-title":"Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies","volume":"7","author":"Ahn","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0255","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/1061186X.2013.831421","article-title":"Polypeptide nanogels with hydrophobic moieties in the cross-linked ionic cores: synthesis, characterization and implications for anticancer drug delivery","volume":"21","author":"Kim","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2015.02.001","article-title":"Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models","volume":"208","author":"Desale","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0265","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0270","doi-asserted-by":"crossref","first-page":"12645","DOI":"10.1038\/ncomms12645","article-title":"Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status","volume":"7","author":"Coscia","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0275","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/labinvest.2017.18","article-title":"Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells","volume":"97","author":"Shenoy","year":"2017","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0280","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0285","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jconrel.2015.09.007","article-title":"Targeted delivery of platinum-taxane combination therapy in ovarian cancer","volume":"220","author":"Desale","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0290","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jcsm.12311","article-title":"Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia","volume":"9","author":"Pin","year":"2018","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0295","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.nano.2012.06.001","article-title":"Polymeric nanogels as vaccine delivery systems","volume":"9","author":"Ferreira","year":"2013","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0300","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1021\/acs.bioconjchem.6b00371","article-title":"Selective and efficient cysteine conjugation by Maleimides in the presence of phosphine reductants","volume":"27","author":"Henkel","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0305","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1016\/j.biomaterials.2011.04.006","article-title":"Folate-decorated nanogels for targeted therapy of ovarian cancer","volume":"32","author":"Nukolova","year":"2011","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1042\/bj2540223","article-title":"Transmembrane signalling at epidermal growth factor receptors overexpressed in NIH 3T3 cells. Phosphoinositide hydrolysis, cytosolic Ca2+ increase and alkalinization correlate with epidermal-growth-factor-induced cell proliferation","volume":"254","author":"Pandiella","year":"1988","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0315","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jconrel.2023.07.033_bb0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.yexcr.2016.06.016","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Wei","year":"2002","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/951724","article-title":"Akt: a double-edged sword in cell proliferation and genome stability","author":"Xu","year":"2012","journal-title":"J. Oncol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002800050855","article-title":"Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice","volume":"43","author":"Newman","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0340","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0345","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biomaterials.2014.10.036","article-title":"Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers","volume":"38","author":"Miteva","year":"2015","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0350","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2015.02.017","article-title":"Determination of polymeric micelles\u2019 structural characteristics, and effect of the characteristics on pharmacokinetic behaviors","volume":"203","author":"Shiraishi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0355","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/17435889.3.5.703","article-title":"Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats","volume":"3","author":"Longmire","year":"2008","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0360","doi-asserted-by":"crossref","unstructured":"A.K. Mitra, D.A. Davis, S. Tomar, L. Roy, H. Gurler, J. Xie, D.D. Lantvit, H. Cardenas, F. Fang, Y. Liu, E. Loughran, J. Yang, M. Sharon Stack, R.E. Emerson, K.D. Cowden Dahl, M. V. Barbolina, K.P. Nephew, D. Matei, J.E. Burdette, In vivo tumor growth of high-grade serous ovarian cancer cell lines, Gynecol. Oncol.. 138 (2015) 372\u2013377. doi:https:\/\/doi.org\/10.1016\/j.ygyno.2015.05.040.","DOI":"10.1016\/j.ygyno.2015.05.040"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0365","first-page":"2941","article-title":"Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management","volume":"21","author":"Gadducci","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140403","article-title":"Skeletal muscle depletion and markers for cancer Cachexia are strong prognostic factors in epithelial ovarian cancer","volume":"10","author":"Aust","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0375","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2005.07.026","article-title":"Prevention and treatment of cancer cachexia: new insights into an old problem","volume":"42","author":"Muscaritoli","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0380","doi-asserted-by":"crossref","first-page":"22001","DOI":"10.18632\/oncotarget.25146","article-title":"Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: alterations in sarcomeric and mitochondrial protein expression","volume":"9","author":"Shum","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0385","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jpm.2011.0192","article-title":"Systematic review of cancer presentations with a median survival of six months or less","volume":"15","author":"Salpeter","year":"2012","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0390","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients","volume":"69","author":"Dewys","year":"1980","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0395","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/1471-2407-10-648","article-title":"Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse","volume":"10","author":"Thivat","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0400","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152007779314044","article-title":"Biochemical mechanisms of cisplatin cytotoxicity","volume":"7","author":"Cepeda","year":"2007","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0410","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/17520363.1.4.513","article-title":"CA125 in ovarian cancer","volume":"1","author":"Scholler","year":"2007","journal-title":"Biomark. Med"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0415","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0028-2243(93)90135-Y","article-title":"CA 125 in gynecological pathology \u2014 a review","volume":"49","author":"Kenemans","year":"1993","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0420","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0425","series-title":"Cochrane Database of Systematic Reviews","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2006"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0430","doi-asserted-by":"crossref","first-page":"8631","DOI":"10.1002\/adfm.201603907","article-title":"Intraperitoneal administration of biointerface-camouflaged upconversion nanoparticles for contrast enhanced imaging of pancreatic cancer","volume":"26","author":"Yuan","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0435","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1191\/0960327102ht261oa","article-title":"Flow cytometric detection of apoptotic bone marrow cells with fractional DNA content after application of WR-2721, cyclophosphamide, cisplatin, and exposure of mice to gamma rays","volume":"21","author":"Mazur","year":"2002","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0440","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z","article-title":"Ovarian carcinoma diagnosis: results of a national ovarian cancer survey","volume":"89","author":"Goff","year":"2000","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.jconrel.2023.07.033_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0450","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/00001813-200109000-00007","article-title":"Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033","volume":"12","author":"Gieseg","year":"2001","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2023.07.033_bb0455","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2011.01.010","article-title":"Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer","volume":"302","author":"Nam","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2023.07.033_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172705","article-title":"Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells","volume":"863","author":"Hamzehlou","year":"2019","journal-title":"Eur. J. Pharmacol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:09:31Z","timestamp":1778504971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923004571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":92,"alternative-id":["S0168365923004571"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.033","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}